TITCK and other pertinent documents.

Directive Compliance: Understand Directive 2010/84/EU on pharmacovigilance and its implications for TURKEY.

Role of TITCK: Recognize the agency’s authority and role in evaluating the safety, effectiveness, and quality of drugs throughout their lifecycle.

Among the primary objectives of pharmacovigilance in Turkey is the continuous assessment of the benefits and risks associated with medicinal products. This includes a focus on preventing adverse effects and ensuring that the therapeutic effects outweigh the risks.

Step 2: Developing a Pharmacovigilance System

The establishment of an effective Pharmacovigilance System (PVS) within your organization is crucial for monitoring drug safety and ensuring compliance with local and global regulations. The following elements outline how to develop this system:

• Creation of a Pharmacovigilance Team: Form a dedicated team comprising qualified personnel with expertise in pharmacology, medicine, and regulatory affairs to be responsible for monitoring and reporting.
• Utilization of Pharmacovigilance Software: Implement software solutions for efficient data collection, case processing, and reporting of ADRs. This enables streamlined operations and adherence to timelines.
• Standard Operating Procedures (SOPs): Establish clear SOPs for the documentation, management, and reporting of ADRs. Compliance with SOPs is mandatory during inspections by regulatory authorities.

Developing a robust PVS requires adequate resources to manage data effectively. Conducting regular training sessions ensures that team members are well-versed in pharmacovigilance principles and the specific context of Turkish regulations.

Step 3: Reporting Adverse Drug Reactions (ADRs)

Efficient ADR reporting is an essential part of pharmacovigilance compliance. In Turkey, healthcare professionals and patients are encouraged to report any suspected ADRs. The following steps should be followed for effective ADR reporting:

• Establishing Reporting Channels: Develop multiple channels for ADR reporting, including email, online portals, and phone hotlines. Ensure these channels are easily accessible to healthcare professionals and patients.
• Collecting Information: Gather comprehensive details about the ADR, including patient demographics, drug involved, timing, and clinical outcome. Having a standardized report form helps maintain consistency.
• Assessing Causality: Conduct causality assessments using validated scales (e.g., Naranjo scale) to determine the likelihood of the drug causing the ADR.

Reporting should be completed within specific timelines: serious ADRs must be reported within 7 days, while non-serious ADRs require a 15-day report time frame as per the TITCK requirements. Additionally, reports must be submitted using the ICH E2E pharmacovigilance guidelines, which support the consistency of safety data across regions.

Step 4: Risk Management Plans (RMPs)

Risk management plans (RMPs) are essential for the identification, assessment, and minimization of risks associated with medicinal products. Following these steps will help in developing an effective RMP in compliance with Turkish regulations:

• Identifying Risks: Begin by identifying all potential risks associated with the product, including its pharmacological effects, patient population, and comorbid conditions that may influence safety.
• Describing Risk Mitigation Strategies: Develop risk minimization strategies tailored to the identified risks. For instance, if a drug is associated with a serious adverse event, consider educational programs for healthcare providers to enhance awareness.
• Monitoring the Effectiveness of Risk Mitigation: Implement systems to monitor the effectiveness of the strategies in real-time and adjust as necessary. Adverse events should be continuously tracked to determine if risk management strategies are effective.

Documentation should include a clear outline of identified risks, proposed mitigation measures, and an evaluation plan to assess the effectiveness of implemented measures over time.

Step 5: Compliance with Post-Marketing Surveillance Obligations

Post-marketing surveillance is a critical phase where the real-world safety and efficacy of pharmaceutical products are assessed. The following actions illustrate pertinent responsibilities for compliance:

• Ongoing Safety Monitoring: Continuous monitoring of product safety in the market is essential. This involves the ongoing collection and analysis of ADR data, with results utilized to update RMPs as necessary.
• Periodic Safety Update Reports (PSURs): Submit PSURs to the TITCK at defined intervals. Ensure that these reports contain cumulative safety information to demonstrate that the benefit-risk balance remains favorable.
• Engagement with Healthcare Professionals: Establish channels for healthcare professional inquiries related to adverse reactions. Stay proactive in responding to any safety concerns raised.

Adhering to post-marketing obligations is vital for maintaining market authorization in Turkey. Any failure to meet these obligations can result in significant compliance issues and regulatory actions from the TITCK.

Step 6: Addressing Compliance Issues and Regulatory Inspections

Regulatory inspections by TITCK assess compliance with pharmacovigilance and risk management regulations. Preparation for these inspections involves the following steps:

• Internal Audits: Conduct regular internal audits to identify compliance gaps. This should include a review of pharmacovigilance reports, risk management strategies, and training compliance for staff.
• Documentation Readiness: Ensure all documentation, including SOPs, training records, and ADR reports, are readily available and organized. Lack of proper documentation could lead to non-compliance findings.
• Mock Inspections: Consider conducting mock inspections to familiarize your team with inspection protocols and to prepare adequately for the interaction with regulatory authorities.

Addressing compliance issues promptly and effectively helps maintain a good standing with the TITCK and ensures ongoing market access. A proactive approach to compliance is critical for addressing any regulatory challenges that may arise.

Step 7: Continuous Improvement and Stakeholder Engagement

The final step in ensuring robust pharmacovigilance and risk management practices lies in the principle of continuous improvement and stakeholder engagement.

• Training and Development Programs: Develop ongoing education programs for staff regarding the latest regulations and best practices in pharmacovigilance.
• Stakeholder Engagement: Engage with healthcare providers, patients, and regulatory bodies to foster communication and enhance safety practices. Consider holding regular meetings to discuss product safety concerns and insights.
• Utilizing Feedback: Collect and analyze feedback from various stakeholders on the pharmacovigilance system and risk management activities to identify areas for improvement.

The goal is to create a culture of safety and compliance that is adaptable to regulatory changes and responsive to stakeholder needs. Establish a feedback loop that fosters continuous improvement of pharmacovigilance practices in alignment with TITCK requirements.